These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
360 related articles for article (PubMed ID: 24718924)
21. Breast cancer predisposition syndromes. Hemel D; Domchek SM Hematol Oncol Clin North Am; 2010 Oct; 24(5):799-814. PubMed ID: 20816575 [TBL] [Abstract][Full Text] [Related]
22. Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. Burt EC; McGown G; Thorncroft M; James LA; Birch JM; Varley JM Br J Cancer; 1999 Apr; 80(1-2):9-10. PubMed ID: 10389970 [TBL] [Abstract][Full Text] [Related]
23. PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome. He X; Saji M; Radhakrishnan D; Romigh T; Ngeow J; Yu Q; Wang Y; Ringel MD; Eng C J Clin Endocrinol Metab; 2012 Nov; 97(11):E2179-87. PubMed ID: 22962422 [TBL] [Abstract][Full Text] [Related]
24. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137 [TBL] [Abstract][Full Text] [Related]
25. Functional studies of a novel germline p53 splicing mutation identified in a patient with Li-Fraumeni-like syndrome. Piao J; Sakurai N; Iwamoto S; Nishioka J; Nakatani K; Komada Y; Mizutani S; Takagi M Mol Carcinog; 2013 Oct; 52(10):770-6. PubMed ID: 22495821 [TBL] [Abstract][Full Text] [Related]
27. RNA polymerase III transcription can be derepressed by oncogenes or mutations that compromise p53 function in tumours and Li-Fraumeni syndrome. Stein T; Crighton D; Boyle JM; Varley JM; White RJ Oncogene; 2002 May; 21(19):2961-70. PubMed ID: 12082526 [TBL] [Abstract][Full Text] [Related]
28. Connection between Tumor Suppressor BRCA1 and PTEN in Damaged DNA Repair. Minami A; Nakanishi A; Ogura Y; Kitagishi Y; Matsuda S Front Oncol; 2014; 4():318. PubMed ID: 25426449 [TBL] [Abstract][Full Text] [Related]
29. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Kuperwasser C; Hurlbut GD; Kittrell FS; Dickinson ES; Laucirica R; Medina D; Naber SP; Jerry DJ Am J Pathol; 2000 Dec; 157(6):2151-9. PubMed ID: 11106587 [TBL] [Abstract][Full Text] [Related]
30. Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Okumura N; Yoshida H; Kitagishi Y; Nishimura Y; Matsuda S Biochem Biophys Res Commun; 2011 Sep; 413(3):395-9. PubMed ID: 21893034 [TBL] [Abstract][Full Text] [Related]
31. Ectodomain-specific E-cadherin antibody suppresses skin SCC growth and reduces tumor grade: a multitargeted therapy modulating RTKs and the PTEN-p53-MDM2 axis. Brouxhon SM; Kyrkanides S; Raja V; Silberfeld A; Teng X; Trochesset D; Cohen J; Ma L Mol Cancer Ther; 2014 Jul; 13(7):1791-802. PubMed ID: 24748654 [TBL] [Abstract][Full Text] [Related]
32. PTEN: one gene, many syndromes. Eng C Hum Mutat; 2003 Sep; 22(3):183-98. PubMed ID: 12938083 [TBL] [Abstract][Full Text] [Related]
33. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
34. Germline SDHx variants modify breast and thyroid cancer risks in Cowden and Cowden-like syndrome via FAD/NAD-dependant destabilization of p53. Ni Y; He X; Chen J; Moline J; Mester J; Orloff MS; Ringel MD; Eng C Hum Mol Genet; 2012 Jan; 21(2):300-10. PubMed ID: 21979946 [TBL] [Abstract][Full Text] [Related]
35. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. Bubien V; Bonnet F; Brouste V; Hoppe S; Barouk-Simonet E; David A; Edery P; Bottani A; Layet V; Caron O; Gilbert-Dussardier B; Delnatte C; Dugast C; Fricker JP; Bonneau D; Sevenet N; Longy M; Caux F; J Med Genet; 2013 Apr; 50(4):255-63. PubMed ID: 23335809 [TBL] [Abstract][Full Text] [Related]
36. The Evolution of Tumors in Mice and Humans with Germline p53 Mutations. Levine AJ; Chan CS; Dudgeon C; Puzio-Kuter A; Hainaut P Cold Spring Harb Symp Quant Biol; 2015; 80():139-45. PubMed ID: 26642854 [TBL] [Abstract][Full Text] [Related]
37. P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Marchal S; Galenne T; Juin P; Becuwe P; Merlin JL Cancer Gene Ther; 2009 Jun; 16(6):498-507. PubMed ID: 19165235 [TBL] [Abstract][Full Text] [Related]
38. PTEN: a new guardian of the genome. Yin Y; Shen WH Oncogene; 2008 Sep; 27(41):5443-53. PubMed ID: 18794879 [TBL] [Abstract][Full Text] [Related]
39. PTEN regulates phospholipase D and phospholipase C. Alvarez-Breckenridge CA; Waite KA; Eng C Hum Mol Genet; 2007 May; 16(10):1157-63. PubMed ID: 17405772 [TBL] [Abstract][Full Text] [Related]
40. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Orloff MS; He X; Peterson C; Chen F; Chen JL; Mester JL; Eng C Am J Hum Genet; 2013 Jan; 92(1):76-80. PubMed ID: 23246288 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]